Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: J Thorac Oncol. 2023 Jan 16;18(5):620–627. doi: 10.1016/j.jtho.2023.01.008

Figure 2: Intracranial activity of selpercatinib.

Figure 2:

The cumulative incidence rates (CIRs) of central nervous system (CNS) progression in patients with (right) and without (left) metastases to the CNS at baseline are shown.